Title : Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.

Pub. Date : 2008 Oct 15

PMID : 18688862






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The effect of simvastatin on RANKL signaling and consequent osteoclastogenesis was investigated. Simvastatin TNF superfamily member 11 Homo sapiens
2 RANKL induced NF-kappaB activation, whereas pretreatment with simvastatin completely suppressed such activation and correlated with suppression of RANKL-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation and IkappaBalpha degradation. Simvastatin TNF superfamily member 11 Homo sapiens
3 Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss. Simvastatin TNF superfamily member 11 Homo sapiens
4 Together, our results indicate that simvastatin inhibits the RANKL-induced NF-kappaB activation pathway that leads to suppression of osteoclastogenesis induced by RANKL and by tumor cells, thereby suggesting its therapeutic potential in osteoporosis and in cancer-related bone loss. Simvastatin TNF superfamily member 11 Homo sapiens